This website is intended for healthcare professionals and patients who have been prescribed Dysport® (Clostridium botulinum type a toxin-haemagglutinin complex) for:
- Symptomatic treatment of focal spasticity affecting the upper limbs in adults
- Symptomatic treatment of focal spasticity in adults affecting the ankle joint due to stroke or traumatic brain injury (TBI)
- Treatment of dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, 2 years of age or older
- Symptomatic treatment of focal spasticity affecting the upper limbs in paediatric cerebral palsy patients, 2 years of age or older
- Treatment of spasmodic torticollis in adults
For a full list of licensed indications, please refer to the Dysport® Summary of Product Characteristics.
Access using the code provided
The information on this website is intended only for healthcare professionals in Ireland prescribing Dysport® (Clostridium botulinum type a toxin-haemagglutinin complex) for adult and paediatric focal spasticity and adult spasmodic torticollis (cervical dystonia) and is not intended for the general public. For a full list of licensed indications, please refer to the Dysport® Summary of Product Characteristics (SmPC).
This website is for promotional purposes only and should not replace the details contained in the Patient Information Leaflet and/or the SmPC.
By entering this website, you are confirming you are a healthcare professional prescribing Dysport® in Ireland.
Reporting adverse events:
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to the Ipsen Medical Information Department on +353 18098256 or pharmacovigilance.uk-ie@ipsen.com.
You are now leaving the Dysport® Ireland website and will be re-directed to www.ipsen.com/uk-ireland/our-medicines.
Reporting adverse events:
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to the Ipsen Medical Information Department on +353 18098256 or pharmacovigilance.uk-ie@ipsen.com.